Form 8-K - Current report:
SEC Accession No. 0001437749-21-002005
Filing Date
2021-02-04
Accepted
2021-02-04 16:07:43
Documents
18
Period of Report
2021-02-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20210203_8k.htm   iXBRL 8-K 38727
2 EXHIBIT 1.1 ex_224342.htm EX-1.1 196091
3 EXHIBIT 5.1 ex_224343.htm EX-5.1 8374
4 EXHIBIT 99.1 ex_224345.htm EX-99.1 10465
5 EXHIBIT 99.2 ex_224346.htm EX-99.2 10617
10 mbrx20210203_8kimg001.jpg GRAPHIC 3620
  Complete submission text file 0001437749-21-002005.txt   471131

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20210202.xsd EX-101.SCH 3699
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20210202_def.xml EX-101.DEF 12360
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20210202_lab.xml EX-101.LAB 16563
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20210202_pre.xml EX-101.PRE 12624
11 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20210203_8k_htm.xml XML 2743
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671999 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 21591218
SIC: 2834 Pharmaceutical Preparations